Introduction
============

Gastric cancer is the fifth most commonly diagnosed cancer worldwide \[[@b1-crt-2016-515]\]. The incidence rates of gastric cancer are the highest in East Asian countries, including Korea \[[@b2-crt-2016-515]\]. In Korea, gastric cancer is the second most common type of cancer, although a gradual decline in incidence has been noted, with annual changes of --0.6% occurring between 1999 and 2013. For Korean males, the incidence of gastric cancer is the highest among all types of cancer \[[@b3-crt-2016-515]\].

Gastric inflammation is a prerequisite for the development of gastric cancer in the multistage model of gastric carcinogenesis \[[@b4-crt-2016-515]\]. One of the main risk factors for gastric cancer is *Helicobacter pylori* infection, which has been classified by the International Agency for Research on Cancer as "carcinogenic to humans (Group 1)" \[[@b5-crt-2016-515]\]. *H. pylori* infection causes a chronic gastric inflammatory response and oxidative stress with a high chance of bacterial proliferation in the stomach that leads to diverse clinical outcomes in humans (e.g., gastritis, peptic ulcers, and gastric cancer) \[[@b6-crt-2016-515]\]. It has been recognized that gastric adenocarcinomas have frequently been found in areas of inflammation in which chronic *H. pylori* progresses over time \[[@b7-crt-2016-515]\]. However, clinical outcomes may differ depending on both genetic (intrinsic) and environmental (extrinsic) factors such as genetic variability of the *H. pylori* strain, genetic background of the infected host with different ethnic groups, and diversity of the diet or lifestyle \[[@b6-crt-2016-515],[@b8-crt-2016-515]\]. Specifically, the inflammatory response can be induced by the virulence properties of *H. pylori* pathogenicity and by the genetic predisposition of inflammatory cytokines related to host immunity \[[@b9-crt-2016-515]\]. The cytokines encoded by the interleukin (IL) genes are thought to contribute to induction of the precancerous stage of gastric atrophy by regulating immune responses and gastric acid secretion and by inhibiting *H. pylori* infection \[[@b10-crt-2016-515]\]. Additionally, the dietary consumption of specific foods and their active constituents may impact the progression of gastric inflammation and carcinogenesis \[[@b11-crt-2016-515]\]. Among diverse foods consumed abundantly in Asian diets, soy products have been reported to have anti-inflammatory properties, and previous studies have confirmed that high soy consumption may reduce the risk of gastric cancer \[[@b12-crt-2016-515]\].

In this context, gastric cancer is believed to be affected by various factors, including genetic susceptibility, cultural diversity, ethnicity, sex, and other environmental influences, such as diets that differ among geographic regions \[[@b13-crt-2016-515]\]. The present study was conducted to investigate whether the combined effect of dietary soy consumption and inflammation-related genetic polymorphisms (*IL10*, *IL2*, *IL13*, and *IL4R*) alters gastric cancer risk.

Materials and Methods
=====================

1. Study participants and data collection
-----------------------------------------

The study subjects were recruited for a gastric cancer research project of the National Cancer Center (NCC), Korea between March 2011 and December 2014. The patients, who were diagnosed with early-stage gastric cancer three months prior to recruitment, were defined as the cases. Patients diagnosed with other cancers within 5 years, advanced gastric cancer, diabetes mellitus, severe systemic or mental disease, women who were pregnant or breastfeeding, and patients who stated that they had changed their dietary pattern due to illnesses were excluded. The controls of this study were recruited among individuals who visited the Center for Cancer Prevention and Detection at the same hospital as the beneficiaries of the National Health Insurance program, were in attendance to receive health examinations, and agreed to participate in the study. Individuals with a history of cancer, diabetes mellitus, gastric ulcers, and *H. pylori* treatment in the control group were excluded. Participants were asked to complete a set of self-administered surveys to obtain information regarding the demographics, medical history, lifestyle, and dietary intake habits. The frequency of cases and controls were matched for gender and 5-year age distributions. A total of 377 gastric cancer cases and 754 healthy controls for whom data on soy product intake and genetic characteristics were available were included in this study, and all of the participants were of Korean origin ([Fig. 1](#f1-crt-2016-515){ref-type="fig"}). The infection status of *H. pylori* was evaluated using the rapid urease test (Pronto Dry, Medical Instruments Corp., Solothurn, Switzerland) and a histological/serological assessment. All of the participating subjects provided written informed consent, and the study protocol was approved by the Institutional Review Board of the National Cancer Center (NCCNCS 11-438).

2. Dietary measurement
----------------------

Individuals were asked to complete a semi-quantitative food frequency questionnaire \[[@b14-crt-2016-515]\] consisting of 106 food items to obtain information regarding regular dietary intake habits from the past 12 months (participants were asked about the average frequency of intake and portion size of specific foods to assess their regular intake during the previous year using the validated food frequency questionnaire). The soy food items measured were legumes, tofu, soymilk, sprouts, and *doenjang* (Korean traditional fermented soybean paste and soybeans), and the intake amount of each item was calculated using CAN-PRO 4.0 (Computer Aided Nutritional Analysis Program, The Korean Nutrition Society, Seoul, Korea). The isoflavone intake level from the five types of soy food consumption was estimated using the Korean Isoflavone database \[[@b15-crt-2016-515]\].

3. Genotype measurement
-----------------------

Genomic DNA was extracted using peripheral blood leukocytes isolated from whole-blood samples obtained from the participants. The Affymetrix Axiom Exom 319 Array (Affymetrix Inc., Santa Clara, CA) platform, including 318,983 variants, was used for genotyping. Genetic markers with deviation from Hardy-Weinberg equilibrium p-values \< 1×10^--6^, a minor allele frequency (MAF) \< 0.01, and a low call rate (\< 90%) were discarded. The genotype imputation was performed using the Asian population (n=504) of 1000 Genome haplotypes phase III integrated variant set release GRch37/hg19 (<http://www.1000genomes.org/>) as a reference panel. Phasing was performed using SHAPIT (v2.r837), and single-nucleotide polymorphism (SNP) imputation was completed using IMPUTE2 (2.3.2). The same quality control criteria were applied after filtering for an INFO score over 0.6. A total of seven variants of *IL10*, *IL2*, *IL13*, and *IL4R* (rs1800871, rs2069763, rs2069762, rs6596090, rs20541, rs7205663, and rs1805010, respectively) were selected. The MAFs of all variants were over 0.15, and imputed variants (rs2069762, rs6596090, rs7205663) had an INFO score above 0.95. Detailed information regarding the variants analyzed in this study can be found in [S1 Table](#SD1-crt-2016-515){ref-type="supplementary-material"}.

4. Statistical analyses
-----------------------

The demographics and general characteristics of the study participants were compared between the case and control subjects using the Student's t test for continuous variables and the chi-square test for categorical variables. The dietary variables were adjusted for total daily calorie intake for statistical analysis using the regression residual method \[[@b16-crt-2016-515]\]. The legume, tofu, soymilk, and sprout intakes were combined to represent nonfermented soy products, and the total soy product intake was calculated by adding all five types of soy foods. Based on the distribution of the control samples, the food intakes were categorized into tertiles for further analysis. Odds ratios (OR) and 95% confidence intervals (CI) of gastric cancer risk were calculated for each soy food group and for isoflavone using multiple logistic regression, with the lowest tertile as a reference group. The estimates of ORs and 95% CIs were adjusted for education level, alcohol consumption status, smoking status, *H. pylori* infection, and engagement in regular exercise. Each genetic variant's risk of gastric cancer was assessed under the dominant model. To analyze the combined effects of soy food intake and genetic polymorphism, a low-intake group and a high-intake group for each type of soy food were categorized according to the median intake level of the control group. OR and the 95% CI of each of the stratified groups were estimated, and the interactions between soy products and SNPs were analyzed by a likelihood ratio test, where the multiplicative interaction term of the genetic polymorphism and soy food intake was added to the logistic regression model. The cases and their individually matched controls were stratified by histological type and the interactions between nonfermented soy product intake and IL polymorphisms were further analyzed. All of the statistical analysis was performed using SAS ver. 9.3 (SAS Institute Inc., Cary, NC).

Results
=======

Daily intakes (g/day) of total soy products, legumes, and sprouts and isoflavone levels (mg/day) were higher in the control group. There were no age or gender differences between the cases and controls because the participants were matched for frequency. The cases had a higher proportion of *H. pylori* infection, nonregular physical exercisers, and current smokers and a lower proportion of college graduates ([Table 1](#t1-crt-2016-515){ref-type="table"}).

Male individuals with the highest tertile total soy product intake had a lower risk for gastric cancer than the lowest tertile group (OR, 0.64; 95% CI, 0.43 to 0.95) in the crude model, but the association was null in the fully adjusted model. A higher intake of nonfermented soy products was associated with reduced cancer risk in the total population (OR, 0.62; 95% CI, 0.42 to 0.89), and the reduced risk was only apparent in males (OR, 0.44; 95% CI, 0.27 to 0.71). However, a higher intake of legumes, which is a subgroup of nonfermented soy, was associated with reduced gastric cancer risk in the total population (OR, 0.67; 95% CI, 0.47 to 0.96) and in females (OR, 0.40; 95% CI, 0.21 to 0.73). Soymilk intake was also inversely associated with gastric cancer risk, but a protective effect of isoflavone was only observed in males ([Table 2](#t2-crt-2016-515){ref-type="table"}). None of the interleukin genetic polymorphisms examined in this study were independently associated with all-type gastric cancer risk ([Table 3](#t3-crt-2016-515){ref-type="table"}); however, increased diffuse-type gastric cancer risk was observed for *IL2* rs2069763, and *IL13* rs6596090 was associated with mixed-type gastric cancer ([S2 Table](#SD2-crt-2016-515){ref-type="supplementary-material"}).

A higher intake of nonfermented soy food among individuals with the C allele of rs2069762 displayed a significant association (OR, 0.46; 95% CI, 0.31 to 0.68), whereas OR was estimated as 0.84 (95% CI, 0.54 to 1.29) among AA homozygotes. The interacting effects for *IL2* rs2069762 and nonfermented soy product intake were significant (p~interaction~=0.039). Several protective effects of nonfermented soy intake were observed for groups stratified by other remaining interleukin SNPs, but no significant interaction was observed. When the effect was assessed according to histological type of cancer, stronger evidence of an interaction between nonfermented soy intake and rs2069762 was observed for intestinal-type gastric cancer (p~interaction~=0.001). A possible interaction between nonfermented soy food and *IL10* rs1800871 was also observed for intestinal-type gastric cancer (p~interaction~=0.033). No significant interaction was found for diffuse-type, and there was evidence of a marginal interacting effect between nonfermented soy products and *IL13* rs20541 (p~interaction~=0.050) for mixed-type gastric cancer ([Table 4](#t4-crt-2016-515){ref-type="table"}). No apparent interaction was observed for total soy, isoflavone, and fermented paste when stratified by IL genetic variants ([S3 Table](#SD3-crt-2016-515){ref-type="supplementary-material"}).

The association between soy product intake, *IL* genetic polymorphism, and gastric cancer risk was further analyzed after stratification by *H. pylori* infection status ([S4 Table](#SD1-crt-2016-515){ref-type="supplementary-material"}-[S6 Table](#SD6-crt-2016-515){ref-type="supplementary-material"}). For the association with each type of soy product, only the *H. pylori* positive groups showed a protective association with nonfermented soy products, legumes, soymilk, and isoflavone, which is consistent with the association results for the total study population. However, uninfected individuals did not display any significant association after adjustment for covariates. Additionally, when the effect of *IL* genetic polymorphisms was analyzed, *IL2* rs2067962 had a significant relationship with the disease among members of the *H. pylori* infection--negative group (OR, 2.88; 95% CI, 1.14 to 7.26).

Discussion
==========

Our findings demonstrate that the dietary intake of nonfermented soy food items was associated with a decrease in gastric cancer risk, whereas there was no independent association between IL genetic polymorphisms and intestinaltype gastric cancer in contrast to the associations observed for diffuse-type and mixed-type gastric cancer risk. Among individuals with higher intake of nonfermented soy products, only those carrying the minor allele C of *IL2* rs2069762 showed a protective effect of soy against gastric cancer risk compared to individuals with different genetic characteristics. This trend was more apparent for intestinal-type gastric cancer risk than diffuse-type.

Gastric cancer is a common diet-related cancers with an etiology that can be explained based on differences in environmental risk factors. Diet has been regarded as a complex environmental factor, with diversity in the common diets of each culture due to different major food sources, cooking or storing methods, and recipes \[[@b11-crt-2016-515]\]. Soy products are abundantly used in Korean dishes, and soybeans and soybeanderived foods are a rich source of bioactive phytochemicals with anti-inflammatory or anti-cancer activity in different types of carcinogenesis \[[@b17-crt-2016-515]\]. Our study demonstrated that consumption of nonfermented soy, including legumes and soymilk, was associated with a significant decrease in gastric cancer risk. However, there was no evidence of an association between gastric cancer risk and the intake of fermented soy products, such as soybean paste, which is frequently used in Korean recipes and known to have a high salt content. According to a comprehensive literature review published by the World Cancer Research Fund and the American Institute for Cancer Research \[[@b18-crt-2016-515]\], salted and salty foods are "probable" factors that increase the risk of gastric cancer, and soy products are classified as "limited suggestive" foods to decrease gastric cancer risk. Recommendations suggest that the dietary intake of nonfermented soy products may provide greater preventive effects against gastric cancer than the consumption of fermented soy products that include high levels of salt, such as preserved vegetables and condiments (e.g., Kimchi, pickles, soy sauce, *doenjang*) according to traditional Korean recipes. Stratification of our results by *H. pylori* infection status suggest that the anti-inflammatory and anti-oxidative effects of soy intake (e.g., nonfermented soy product, legumes, soymilk, and isoflavone) are helpful for individuals who are already susceptible to chronic inflammation or gastritis due to *H. pylori* infection. We hypothesized that dietary nonfermented soy intake may reduce the risk of gastric cancer by modulating immune parameters in favor of anti-cancer immune responses in humans \[[@b4-crt-2016-515],[@b19-crt-2016-515]\]. Soy is well known as a beneficial food containing phytochemicals (e.g., isoflavone) that have anti-inflammatory and anti-oxidative effects. Phytochemicals generated in plants may overcome inflammation and infection by immune modulation through its components \[[@b20-crt-2016-515]\]. Specifically, soy is known to potentiate immunological functions of lymphocyte proliferation, cellular and humoral immune responses, thymocyte differentiation, and tumor immunity \[[@b21-crt-2016-515]\]. We expected that soy isoflavone would benefit individuals by inhibiting the progression of inflammation and gastric carcinogenesis through the anti-carcinogenic properties of phytochemicals (e.g., phytoestrogens) \[[@b22-crt-2016-515]\]. Our findings demonstrate that the intake of soy isoflavone is associated with a decrease in gastric cancer risk, particularly in males, whereas there was no association of risk in females. Moreover, reduced gastric cancer risk was shown in females consuming legumes, although no association was observed in males. Further studies are required to support the role of soy phytochemicals as phytoestrogens in association with gastric cancer and to reveal the related biological mechanism, gender difference, and genetic susceptibility.

Genetic variants encoding cytokines may influence an individual's inflammatory response and health or clinical outcomes \[[@b4-crt-2016-515]\]. Genetic polymorphisms of cytokines have been associated with variations in the level of transcription and expression of cytokines that can exert activities in human diseases \[[@b23-crt-2016-515]\]. Many candidate gene studies have been conducted, and the results have indicated that polymorphisms in cytokine genes influence the susceptibility to gastric cancer and clinical outcomes (e.g., the course, symptoms, and treatments related to gastric cancer) \[[@b23-crt-2016-515],[@b24-crt-2016-515]\]. Cytokine production generated by immune and inflammatory cells is one of the major tumor-promoting mechanisms. Cytokines can have either pro- or anti-inflammatory activity and may be involved in immunomodulatory activity depending on the microenvironment \[[@b24-crt-2016-515]\]. The immunomodulatory response is served by the balance between anti-inflammatory cytokines (e.g., IL4, *IL10*, and *IL13*) and pro-inflammatory cytokines (e.g., *IL2*) \[[@b25-crt-2016-515]\]. With regard to gastric cancer, cytokine polymorphisms of the host are the most studied risk factor and result in an increased risk of gastric cancer by decreasing the anti-inflammatory host reaction or increasing the pro-inflammatory response \[[@b26-crt-2016-515]\]. We hypothesized that the risk for gastric cancer may be modified by IL genetic variations, which result in differences in immunomodulatory activity among individuals. Independent risk associations between IL polymorphisms and intestinal-type gastric cancer were not observed in this study, but an association between *IL2* rs2069763 and diffuse-type gastric cancer risk was observed. Different effects of IL genetic polymorphisms for different histological types of gastric cancer are anticipated since the etiology of cancer development is diverse \[[@b7-crt-2016-515],[@b27-crt-2016-515]\]. Diffuse-type gastric cancer is more closely associated with genetic susceptibility, whereas environmental factors, such as lifestyle and dietary patterns, reportedly have a greater influence on intestinal-type gastric cancer \[[@b27-crt-2016-515],[@b28-crt-2016-515]\]. In addition, the genetic susceptibility to immune responses may be a strong risk factor for the development of gastric cancer among individuals without *H. pylori* infection.

A suggestive interaction was detected between nonfermented soy intake and *IL2* polymorphism (rs2069762) for gastric cancer risk, especially for intestinal-type. The *IL2* gene is an important cytokine family member that plays a critical role in carcinogenesis through the proliferation of activated T lymphocytes and participates in termination of the lymphocyte response by inducing suppressive T cells \[[@b29-crt-2016-515]\]. The *IL2* gene polymorphism, which is associated with an increased risk of gastric atrophy induced by *H. pylori* infection, might predispose individuals to gastric cancer \[[@b10-crt-2016-515]\]. Previous studies have investigated the association between rs2069762 polymorphism and cancer risk, but the results remain controversial \[[@b10-crt-2016-515],[@b29-crt-2016-515]\]. We found a suggestive interactive effect between by rs2069762 and nonfermented soy consumption on intestinal-type gastric cancer risk, which suggests a possible interactive role between soy phytochemicals and the pro-inflammatory properties of *IL2* cytokines. No previous epidemiological studies have examined the effects of the interaction between soybean product intake and *IL2* genetic variants on modification of gastric cancer risk, which is one of the strengths of this study. rs1800871 of *IL10* also showed a suggestive interacting effect with nonfermented soy product intake on intestinal-type gastric cancer risk, which confirms the results of a previous study that examined the interactive effect between soy and *IL10* \[[@b30-crt-2016-515]\] and suggested a possible interaction between the anti-inflammatory properties of cytokines and soybean products. Further epidemiological and experimental studies are required to support this unclear interactive effect.

It should be noted that this study has several strengths and limitations. The dietary data used in the analysis were more robust than those employed in previous studies focusing on the interactive effect between soy consumption and inflammatory genes with regard to gastric cancer risk. In addition, the dietary data included various types of soy products that were all quantitatively comparable (e.g., g/day), whereas similar studies utilized dietary data that represented only the frequency of intake (e.g., times per week). Although the dietary data including detailed soy items strengthened this study, recall or reporting bias may be present. Thus, this study was limited with regard to representing changes in dietary or lifestyle habits due to illness (whether the change preceded of followed illness). Additionally, our statistical p-values were not significant if a strict multiple comparison adjustment was applied. Nonetheless, our findings imply a suggestive interaction between soy intake and *IL2* genotypes.

In conclusion, our study of a Korean population suggested that the interaction between *IL2* rs2069762 and nonfermented soy intake may modify the risk of gastric cancer. The findings of this study suggest that an interaction between a variant of the *IL2* gene and phytochemicals in nonfermented soy products has a preventative effect on gastric cancer, and that this observation may support the promotion of dietary intervention against gastric cancer on the basis of potential geneenvironment interactions. Further studies are required to replicate the results and to clarify the corresponding biological mechanisms involved in gastric carcinogenesis.
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###### 

General characteristics of study participants, stratified by cancer status

  Characteristic                                                      Case (n=377)      Control (n=754)   p-value^[a)](#tfn1-crt-2016-515){ref-type="table-fn"}^
  ------------------------------------------------------------------- ----------------- ----------------- --------------------------------------------------------
  **Age (yr)**                                                        53.90±9.19        53.83±9.05        0.900
  **Sex**                                                                                                 
   Male                                                               246 (65.25)       492 (65.25)       \> 0.999
   Female                                                             131 (34.75)       262 (34.75)       
  **Histological type**                                                                                   
   Intestinal                                                         144 (38.20)                         
   Diffuse                                                            151 (40.05)                         
   Mixed                                                              53 (14.06)                          
   Missing                                                            29 (7.69)                           
  **Alcohol drinking status**                                                                             
   Non-drinker                                                        111 (29.44)       218 (28.91)       0.358
   Ex-drinker                                                         38 (10.08)        58 (7.69)         
   Current drinker                                                    228 (60.48)       478 (63.40)       
  **Smoking status**                                                                                      
   Non-smoker                                                         152 (40.32)       344 (45.62)       0.001
   Ex-smoker                                                          110 (29.18)       256 (33.95)       
   Current smoker                                                     115 (30.50)       154 (20.42)       
  **Education**                                                                                           
   Elementary                                                         54 (14.36)        43 (5.97)         \< 0.001
   Middle-high                                                        237 (63.03)       295 (40.97)       
   University                                                         85 (22.61)        382 (53.06)       
  **Regular exercise**                                                                                    
   Yes                                                                136 (36.07)       416 (55.39)       \< 0.001
   No                                                                 241 (63.93)       335 (44.61)       
  ***Helicobacter pylori* infection**                                                                     
   Negative                                                           28 (7.43)         288 (38.20)       \< 0.001
   Positive                                                           349 (92.57)       466 (61.80)       
  **Dietary intake^[b)](#tfn2-crt-2016-515){ref-type="table-fn"}^**                                       
   Isoflavone(mg/day)                                                 13.82±9.74        15.56±12.22       0.009
   Legumes (g/day)                                                    3.99±7.07         5.80±10.97        0.001
   Tofu (g/day)                                                       36.10±30.73       38.45±33.30       0.252
   Soymilk (g/day)                                                    122.76±1,210.09   337.6±5,904.90    0.338
   Sprouts (g/day)                                                    14.08±16.18       16.49±19.92       0.029
   Soybean paste (g/day)                                              6.32±7.81         5.99±7.21         0.482
   Total soy product (g/day)                                          71.75±51.61       82.88±77.25       0.005

Values are presented as mean±standard deviation or number (%).

Significant difference between case and control obtained by Student\'s t test and chi-square test,

Adjusted for total daily calorie intake.

###### 

Associations of soy products with gastric cancer risk, stratified by gender

                                      Total (n=1,131)   Male (n=738)   Female (n=393)                                                                                                                                                                                       
  ----------------------------------- ----------------- -------------- ---------------- ------------------ ------------------ ------------------ ------------- ------------------ ------------------ ------------------ ------------- ------------------ ------------------ ------------------
  **Total soy product**                                                                                                                                                                                                                                                     
                                      T1                251 (33.29)    133 (35.28)      1.00               1.00               165 (33.54)        88 (38.77)    1.00               1.00               86 (32.82)         45 (34.35)    1.00               1.00               
                                      T2                252 (33.42)    140 (37.14)      1.05 (0.78-1.41)   1.23 (0.88-1.72)   165 (33.54)        103 (41.87)   1.17 (0.82-1.67)   1.34 (0.89-2.02)   87 (33.21)         37 (28.24)    0.81 (0.48-1.38)   0.98 (0.54-1.79)   
                                      T3                251 (33.29)    104 (27.59)      0.78 (0.57-1.07)   0.85 (0.59-1.20)   162 (32.93)        55 (22.36)    0.64 (0.43-0.95)   0.69 (0.43-1.09)   89 (33.97)         49 (37.40)    1.05 (0.64-1.74)   1.07 (0.61-1.89)   
  **Non-fermented soy product**                                                                                                                                                                                                                                             
                                      T1                251 (33.29)    144 (38.20)      1.00               1.00               166 (33.74)        102 (41.46)   1.00               1.00               85 (32.44)         42 (32.06)    1.00               1.00               
                                      T2                251 (33.29)    150 (39.79)      1.04 (0.78-1.39)   1.13 (0.81-1.56)   167 (33.94)        102 (41.46)   0.99 (0.70-1.41)   1.14 (0.76-1.71)   84 (32.06)         48 (36.64)    1.15 (0.69-1.93)   1.07 (0.60-1.92)   
                                      T3                252 (33.42)    83 (22.02)       0.57 (0.42-0.79)   0.62 (0.43-0.90)   159 (32.32)        42 (17.07)    0.43 (0.28-0.65)   0.44 (0.27-0.71)   93 (35.50)         41 (31.30)    0.89 (0.53-1.50)   0.97 (0.54-1.77)   
                                      Legumes                                                                                                                                                                                                                               
                                                        T1             252 (33.42)      149 (39.52)        1.00               1.00               187 (38.01)   101 (41.06)        1.00               1.00               65 (24.81)    48 (36.64)         1.00               1.00
                                                        T2             251 (33.29)      125 (33.16)        0.84 (0.63-1.13)   0.94 (0.67-1.31)   158 (32.11)   78 (31.71)         0.91 (0.64-1.32)   1.01 (0.67-1.52)   93 (35.50)    47 (35.88)         0.68 (0.41-1.14)   0.75 (0.41-1.35)
                                                        T3             251 (33.29)      103 (27.32)        0.69 (0.51-0.94)   0.67 (0.47-0.96)   147 (29.88)   67 (27.24)         0.84 (0.58-1.23)   0.89 (0.58-1.39)   104 (39.69)   36 (27.48)         0.47 (0.28-0.80)   0.40 (0.21-0.73)
                                      Tofu                                                                                                                                                                                                                                  
                                                        T1             252 (33.42)      142 (37.67)        1.00               1.00               170 (34.55)   98 (39.84)         1.00               1.00               82 (31.30)    44 (33.59)         1.00               1.00
                                                        T2             250 (33.16)      109 (28.91)        0.77 (0.57-1.05)   0.79 (0.56-1.12)   157 (31.91)   73 (29.67)         0.81 (0.56-1.17)   0.86 (0.56-1.31)   93 (35.50)    36 (27.48)         0.72 (0.42-1.23)   0.66 (0.63-1.21)
                                                        T3             252 (33.42)      126 (33.42)        0.89 (0.66-1.19)   0.91 (0.65-1.28)   165 (33.54)   75 (30.49)         0.79 (0.55-1.14)   0.79 (0.52-1.21)   87 (33.21)    51 (38.93)         1.09 (0.66-1.81)   1.12 (0.53-1.99)
                                      Soymilk                                                                                                                                                                                                                               
                                                        T1             252 (33.42)      173 (45.89)        1.00               1.00               170 (34.55)   115 (46.75)        1.00               1.00               82 (31.30)    58 (44.27)         1.00               1.00
                                                        T2             251 (33.29)      111 (29.44)        0.64 (0.48-0.87)   0.69 (0.49-0.96)   158 (32.11)   74 (30.08)         0.69 (0.48-1.00)   0.74 (0.49-1.12)   93 (35.50)    37 (28.24)         0.56 (0.34-0.94)   0.60 (0.34-1.08)
                                                        T3             251 (33.29)      93 (34.67)         0.54 (0.40-0.73)   0.61 (0.43-0.87)   164 (33.33)   57 (23.17)         0.51 (0.35-0.75)   0.60 (0.39-0.92)   87 (33.21)    36 (27.48)         0.59 (0.35-0.98)   0.63 (0.35-1.13)
                                      Sprouts                                                                                                                                                                                                                               
                                                        T1             251 (33.29)      146 (38.73)        1.00               1.00               171 (34.76)   105 (42.68)        1.00               1.00               80 (30.53)    41 (31.30)         1.00               1.00
                                                        T2             252 (33.42)      119 (31.56)        0.81 (0.60-1.09)   0.90 (0.64-1.26)   163 (33.13)   76 (30.89)         0.76 (0.53-1.09)   0.84 (0.55-1.28)   89 (33.97)    43 (32.82)         0.94 (0.56-1.59)   0.99 (0.54-1.79)
                                                        T3             251 (33.29)      112 (28.71)        0.77 (0.57-1.04)   0.96 (0.61-1.21)   158 (32.11)   65 (26.42)         0.67 (0.46-0.98)   0.72 (0.46-1.11)   93 (35.50)    47 (35.88)         0.99 (0.59-1.65)   1.12 (0.62-2.02)
  **Fermented soy product (paste)**                                                                                                                                                                                                                                         
                                      T1                252 (33.42)    122 (32.36)      1.00               1.00               164 (33.33)        87 (35.37)    1.00               1.00               88 (33.59)         35 (26.72)    1.00               1.00               
                                      T2                251 (33.29)    116 (30.77)      0.96 (0.70-1.30)   0.97 (0.68-1.37)   164 (33.33)        75 (30.49)    0.86 (0.59-1.26)   0.93 (0.60-1.43)   87 (33.21)         41 (31.30)    1.19 (0.69-2.03)   1.06 (0.58-1.94)   
                                      T3                251 (33.29)    139 (36.87)      1.14 (0.85-1.54)   1.08 (0.77-1.51)   164 (33.33)        84 (34.15)    0.97 (0.67-1.40)   0.90 (0.59-1.38)   87 (33.21)         55 (41.98)    1.59 (0.95-2.67)   1.46 (0.89-2.63)   
  **Isoflavone**                                                                                                                                                                                                                                                            
                                      T1                251 (33.29)    137 (36.34)      1.00               1.00               166 (33.74)        92 (37.40)    1.00               1.00               85 (32.44)         45 (34.35)    1.00               1.00               
                                      T2                252 (33.42)    144 (38.20)      1.05 (0.78-1.40)   1.13 (0.81-1.58)   162 (32.93)        100 (40.65)   1.11 (0.78-1.59)   1.14 (0.76-1.72)   90 (34.35)         44 (33.59)    0.92 (0.55-1.54)   1.06 (0.59-1.89)   
                                      T3                251 (33.29)    96 (25.46)       0.70 (0.51-0.96)   0.70 (0.49-1.00)   164 (33.33)        54 (21.95)    0.59 (0.40-0.89)   0.63 (0.40-0.99)   87 (33.21)         42 (32.06)    0.91 (0.54-1.53)   0.82 (0.45-1.49)   

Criteria for tertile groups (total calorie intake adjusted); total soy product (g/day): T1 ≤ 48.39, T2 48.39-86.20, T3 \> 86.20; non-fermented soy product (g/day): T1 ≤ 42.95, T2 42.95-85.54, T3 \> 85.54; legumes (g/day): T1 ≤ 1.35, T2 1.35-3.19, T3 \> 3.19; tofu (g/day): T1 ≤ 20.47, T2 20.47-40.05, T3 \> 40.05; soymilk (g/day): T1 ≤ 4.24E-9, T2 4.24E-9-3.55, T3 \> 3.55; sprouts (g/day): T1 ≤ 6.99, T2 6.99-15.89, T3 \> 15.89; paste (g/day): T1 ≤ 2.29, T2 2.29-5.78, T3 \> 5.78; isoflavone (mg/day): T1 ≤ 8.91, T2 8.91-17.39, T3 \> 17.39. OR, odds ratio; CI, confidence interval; T, tertile.

Adjusted by education, alcohol consumption, smoking status, *Helicobacter pylori* infection, and regular exercise.

###### 

Associations of interleukin genetic polymorphisms (dominant model) with gastric cancer risk

  Gene     rs No.           No. (%)       OR (95% CI)                       
  -------- ----------- ---- ------------- -------------- ------------------ ------------------
  *IL10*   rs1800871   AA   368 (48.81)   173 (45.89)    1                  1
                       G+   386 (51.19)   204 (54.11)    1.12 (0.88-1.44)   1.06 (0.80-1.41)
  *IL2*    rs2069763   AA   226 (29.97)   1111 (29.44)   1                  1
                       C+   528 (70.03)   266 (70.56)    1.03 (0.78-1.35)   1.19 (0.88-1.62)
           rs2069762   AA   358 (47.73)   165 (43.77)    1                  1
                       C+   392 (52.27)   212 (56.23)    1.17 (0.92-1.51)   1.23 (0.93-1.64)
  *IL13*   rs6596090   GG   517 (70.24)   255 (69.29)    1                  1
                       A+   219 (29.76)   113 (30.71)    1.05 (0.80-1.37)   1.04 (0.77-1.43)
           rs20541     GG   366 (48.54)   185 (49.07)    1                  1
                       A+   388 (51.46)   192 (50.93)    0.98 (0.76-1.25)   0.86 (0.65-1.14)
  *IL4R*   rs7205663   TT   259 (34.35)   126 (33.42)    1                  1
                       C+   495 (65.65)   251 (66.58)    1.04 (0.80-1.35)   0.99 (0.73-1.33)
           rs1805010   GG   253 (33.55)   126 (33.42)    1                  1
                       A+   501 (66.45)   251 (66.58)    1.01 (0.77-1.31)   0.95 (0.70-1.28)

OR, odds ratio; CI, confidence interval.

Adjusted by education, alcohol consumption, smoking status, *Helicobacter pylori* infection, and regular exercise.

###### 

Associations and interaction of interleukin genetic polymorphisms (dominant model) and non-fermented soy intake with gastric cancer risk stratified by histological type

  Gene SNP               Allele group   Soy intake   All types     Intestinal    Diffuse             Mixed                                                                                                                                                                                   
  ---------------------- -------------- ------------ ------------- ------------- ------------------- ------------------- ------- ------------- ------------ ------------------- ------- ------------- ------------ ------------------- ------- ------------ ------------ ------------------- -------
  ***IL10* rs1800871**                                                                                                                                                                                                                                                                       
                         AA             Low          185 (50.27)   112 (64.74)   1                   1                   0.342   65 (48.87)    42 (70.00)   1                   0.033   80 (51.28)    43 (56.58)   1                   0.226   24 (48.00)   15 (68.18)   1                   0.525
                                        High         183 (49.73)   61 (35.26)    0.55 (0.38 -0.80)   0.50 (0.33 -0.77)           68 (51.13)    18 (30.00)   0.34 (0.16 -0.74)           76 (48.72)    33 (43.42)   0.69 (0.37 -1.31)           26 (52.00)   7 (31.82)    0.46 (0.14 -1.46)   
                         G+             Low          192 (49.74)   131 (64.22)   1                   1                           81 (52.26)    47 (55.95)   1                           64 (43.84)    52 (69.33)   1                           28 (50.00)   20 (64.52)   1                   
                                        High         194 (50.26)   73 (35.78)    0.55 (0.39 -0.78)   0.70 (0.47 -1.04)           74 (47.74)    37 (44.05)   0.98 (0.53 -1.82)           82 (56.16)    23 (30.67)   0.44 (0.23 -0.88)           28 (50.00)   11 (35.48)   0.71 (0.23 -2.17)   
  ***IL2* rs2069763**                                                                                                                                                                                                                                                                        
                         AA             Low          120 (53.10)   69 (62.16)    1                   1                   0.344   43 (53.75)    21 (51.22)   1                   0.157   52 (51.49)    24 (63.16)   1                   0.391   14 (48.28)   15 (65.22)   1                   0.982
                                        High         106 (46.90)   42 (37.84)    0.69 (0.43 -1.10)   0.75 (0.44 -1.29)           37 (46.25)    20 (48.78)   1.23 (0.51 -2.97)           49 (48.51)    14 (36.84)   0.77 (0.31 -1.94)           15 (51.72)   8 (34.78)    0.42 (0.10 -1.86)   
                         C+             Low          257 (48.67)   174 (65.41)   1                   1                           103 (49.52)   68 (66.02)   1                           92 (45.77)    71 (62.83)   1                           38 (49.35)   20 (66.67)   1                   
                                        High         271 (51.33)   92 (34.59)    0.50 (0.37 -0.68)   0.53 (0.37 -0.75)           105 (50.48)   35 (33.98)   0.48 (0.27 -0.86)           109 (54.23)   42 (37.17)   0.45 (0.26 -0.78)           39 (50.65)   10 (33.33)   0.66 (0.24 -1.81)   
  ***IL2* rs2069762**                                                                                                                                                                                                                                                                        
                         AA             Low          184 (51.40)   99 (60.00)    1                   1                   0.039   77 (53.47)    30 (47.62)   1                   0.001   67 (47.86)    41 (64.06)   1                   0.626   23 (51.11)   19 (67.86)   1                   0.998
                                        High         174 (48.60)   66 (40.00)    0.71 (0.49 -1.03)   0.84 (0.54 -1.29)           67 (46.53)    33 (52.38)   1.54 (0.76 -3.10)           73 (52.14)    23 (35.94)   0.63 (0.61 -1.30)           22 (48.89)   9 (32.14)    0.44 (0.13 -1.44)   
                         C+             Low          192 (48.98)   144 (67.92)   1                   1                           69 (48.25)    59 (72.84)   1                           76 (47.50)    54 (62.07)   1                           29 (48.33)   16 (64.00)   1                   
                                        High         200 (51.02)   68 (32.08)    0.45 (0.32 -0.64)   0.46 (0.31 -0.68)           74 (51.75)    22 (27.16)   0.28 (0.14 -0.57)           84 (52.50)    33 (37.93)   0.50 (0.27 -0.92)           31 (51.67)   9 (36.00)    0.72 (0.23 -2.28)   
  ***IL13* rs6596090**                                                                                                                                                                                                                                                                       
                         GG             Low          270 (52.22)   169 (66.27)   1                   1                   0.972   108 (53.20)   60 (65.22)   1                   0.677   101 (49.75)   63 (62.38)   1                   0.856   36 (51.43)   30 (71.43)   1                   0.919
                                        High         247 (47.78)   86 (33.73)    0.56 (0.41 -0.76)   0.58 (0.41 -0.82)           95 (46.80)    32 (34.78)   0.56 (0.31 -1.01)           102 (50.25)   38 (37.62)   0.56 (0.32 -0.97)           34 (48.57)   12 (28.57)   0.58 (0.22 -1.54)   
                         A+             Low          102 (46.58)   71 (62.83)    1                   1                           37 (48.05)    27 (57.45)   1.00                        40 (43.48)    31 (64.58)   1.00                        15 (45.45)   5 (55.56)    1.00                
                                        High         117 (53.42)   42 (37.17)    0.52 (0.32 -0.82)   0.60 (0.35 -1.04)           40 (51.95)    20 (42.55)   0.69 (0.27 -1.73)           52 (56.52)    17 (35.42)   0.48 (0.20 -1.14)           18 (54.55)   4 (44.44)    0.65 (0.09 -4.79)   
  ***IL13* rs20541**                                                                                                                                                                                                                                                                         
                         GG             Low          187 (51.09)   119 (64.32)   1                   1                   0.549   72 (52.17)    40 (62.50)   1                   0.922   74 (48.37)    50 (62.50)   1                   0.724   28 (54.90)   17 (65.38)   1                   0.050
                                        High         179 (48.91)   66 (35.68)    0.58 (0.40 -0.83)   0.63 (0.42 -0.96)           66 (47.83)    24 (37.50)   0.63 (0.31 -1.27)           79 (51.63)    30 (37.50)   0.48 (0.25 -0.91)           23 (45.10)   9 (34.62)    1.74 (0.42 -7.16)   
                         A+             Low          190 (48.97)   124 (64.58)   1                   1                           74 (49.33)    49 (61.25)   1.00                        70 (46.98)    45 (的.38)   1.00                        24 (43.64)   18 (66.67)   1.00                
                                        High         198 (51.03)   68 (35.42)    0.53 (0.37 -0.75)   0.55 (0.37 -0.82)           76 (50.67)    31 (38.75)   0.65 (0.34 -1.26)           79 (53.02)    26 (36.62)   0.60 (0.31 -1.18)           31 (56.36)   9 (33.33)    0.27 (0.09 -0.85)   
  ***IL4R* rs7205663**                                                                                                                                                                                                                                                                       
                         TT             Low          129 (49.81)   83 (65.87)    1                   1                   0.955   54 (52.94)    31 (64.58)   1                   0.592   43 (44.33)    33 (64.71)   1                   0.710   16 (45.71)   14 (73.68)   1                   0.660
                                        High         130 (50.19)   43 (34.13)    0.51 (0.33 -0.80)   0.60 (0.36 -1.00)           48 (47.06)    17 (35.42)   0.53 (0.23 -1.22)           54 (55.67)    18 (35.29)   0.52 (0.23 -1.17)           19 (54.29)   5 (26.32)    0.51 (0.08 -3.11)   
                         C+             Low          248 (50.10)   160 (63.75)   1                   1                           92 (49.46)    58 (60.42)   1                           101 (49.27)   62 (62.00)   1.00                        36 (50.70)   21 (61.76)   1.00                
                                        High         247 (49.90)   91 (36.25)    0.57 (0.42 -0.78)   0.61 (0.43 -0.87)           94 (50.54)    38 (39.58)   0.70 (0.39 -1.26)           104 (50.73)   38 (38.00)   0.59 (0.34 -1.04)           35 (49.30)   13 (38.24)   0.58 (0.22 -1.57)   
  ***IL4R* rs1805010**                                                                                                                                                                                                                                                                       
                         GG             Low          123 (48.62)   84 (66.67)    1                   1                   0.400   52 (52.00)    33 (68.75)   1                   0.129   45 (46.39)    28 (59.57)   1                   0.827   14 (40.00)   16 (76.19)   1                   0.288
                                        High         130 (51.38)   42 (33.33)    0.47 (0.30 -0.74)   0.51 (0.31 -0.85)           48 (48.00)    15 (31.25)   0.37 (0.16 -0.88)           52 (53.61)    19 (40.43)   0.63 (0.28 -1.42)           21 (60.00)   5 (23.81)    0.29 (0.06 -1.46)   
                         A+             Low          254 (50.70)   159 (63.35)   1                   1                           94 (50.00)    56 (58.33)   1                           99 (48.29)    67 (64.42)   1                           38 (53.52)   19 (59.38)   1                   
                                        High         247 (49.30)   92 (36.65)    0.60 (0.44 -0.81)   0.66 (0.46 -0.94)           94 (50.00)    40 (41.67)   0.84 (0.47 -1.51)           106 (51.71)   37 (35.58)   0.55 (0.31 -0.97)           33 (46.48)   13 (40.63)   0.79 (0.29 -2.13)   

Criteria for high and low non-fermented soy product intake groups (total calorie intake adjusted, g/day): low ≤ 64.51, high \> 64.51. OR, odds ratio; CI, confidence interval.

Adjusted by age, sex, education, alcohol consumption, smoking status, *Helicobacter pylori* infection, and regular exercise.

[^1]: Sarah Yang and Yoon Park contributed equally to this work.
